$MRK

$MRK - Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026…

$MRK - Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-relate…

$MRK - Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS…

$MRK Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)…

$MRK MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH SCIBRUNCH THERAPEUTICS FOR SPR2015, AN INVESTIGATIONAL ORAL KRAS G12D (ON) INHIBITOR (D…

$MRK - Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Volunta…

$MRK - U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recen…

$MRK - Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pem…

$MRK Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembr…

$MRK - Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adu…

$MRK MERCK RECEIVES POSITIVE EU CHMP OPINION FOR KEYTRUDA® (PEMBROLIZUMAB) PLUS PADCEV® (ENFORTUMAB VEDOTIN-EJFV)…

$MRK Merck veteran and psychedelics developer tapped for top FDA job…

$MRK MERCK & CO INC : GUGGENHEIM RAISES TARGET PRICE TO $170 FROM $146…